<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Microbiol</journal-id><journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Microbiology</journal-title></journal-title-group><issn pub-type="epub">1664-302X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098349</article-id><article-id pub-id-type="doi">10.3389/fmicb.2025.1570764</article-id><article-categories><subj-group subj-group-type="heading"><subject>Microbiology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Combined inactivation of the SOS response with TCA fumarases and the adaptive response enhances antibiotic susceptibility against <italic>Escherichia coli</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Murillo-Torres</surname><given-names>Marina</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2964261/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/></contrib><contrib contrib-type="author"><name><surname>Pe&#x000f1;alver-Fern&#x000e1;ndez</surname><given-names>Isabel Mar&#x000ed;a</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Quero-Delgado</surname><given-names>Marta</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Diaz-Diaz</surname><given-names>Sara</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/3010640/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Romero-Mu&#x000f1;oz</surname><given-names>Mar&#x000ed;a</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2944842/overview"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Recacha</surname><given-names>Esther</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1198303/overview"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Docobo-P&#x000e9;rez</surname><given-names>Fernando</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/408554/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Rodr&#x000ed;guez-Mart&#x000ed;nez</surname><given-names>Jos&#x000e9; Manuel</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/45741/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Departamento de Microbiolog&#x000ed;a, Facultad de Medicina, Universidad de Sevilla</institution>, <addr-line>Sevilla</addr-line>, <country>Spain</country></aff><aff id="aff2"><sup>2</sup><institution>Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen Macarena / CSIC / Universidad de Sevilla</institution>, <addr-line>Sevilla</addr-line>, <country>Spain</country></aff><aff id="aff3"><sup>3</sup><institution>Unidad Cl&#x000ed;nica de Enfermedades Infecciosas y Microbiolog&#x000ed;a, Hospital Universitario Virgen Macarena</institution>, <addr-line>Sevilla</addr-line>, <country>Spain</country></aff><aff id="aff4"><sup>4</sup><institution>Centro de Investigaci&#x000f3;n Biom&#x000e9;dica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country></aff><author-notes><fn fn-type="edited-by" id="fn0002"><p>Edited by: Yuji Morita, Meiji Pharmaceutical University, Japan</p></fn><fn fn-type="edited-by" id="fn0003"><p>Reviewed by: Michael Benedik, Texas A&#x00026;M University, United States</p><p>Mark Ambrose, University of Tasmania, Australia</p></fn><corresp id="c001">*Correspondence: Jos&#x000e9; Manuel Rodr&#x000ed;guez-Mart&#x000ed;nez, <email>jmrodriguez@us.es</email></corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1570764</elocation-id><history><date date-type="received"><day>04</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Murillo-Torres, Pe&#x000f1;alver-Fern&#x000e1;ndez, Quero-Delgado, Diaz-Diaz, Romero-Mu&#x000f1;oz, Recacha, Docobo-P&#x000e9;rez and Rodr&#x000ed;guez-Mart&#x000ed;nez.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Murillo-Torres, Pe&#x000f1;alver-Fern&#x000e1;ndez, Quero-Delgado, Diaz-Diaz, Romero-Mu&#x000f1;oz, Recacha, Docobo-P&#x000e9;rez and Rodr&#x000ed;guez-Mart&#x000ed;nez</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec id="sec1"><title>Introduction</title><p>Targeting bacterial DNA damage responses such as the SOS response represents a promising strategy for enhancing the efficacy of existing antimicrobials. This study focuses on a recently discovered DNA damage response mechanism involving tricarboxylic acid cycle (TCA) fumarases and the adaptive response, crucial for <italic>Escherichia coli</italic> survival in the presence of genotoxic methyl methanesulfonate (MMS). We investigated whether this pathway contributes to protection against antibiotics, either separately or in combination with the SOS response.</p></sec><sec id="sec2"><title>Methods</title><p>An isogenic collection of <italic>E. coli</italic> BW25113 mutants was used, including strains deficient in fumarases (&#x00394;<italic>fumA</italic>, &#x00394;<italic>fumB</italic>, &#x00394;<italic>fumC</italic>) and the adaptive response (&#x00394;<italic>alkA</italic>, &#x00394;<italic>alkB,</italic> &#x00394;<italic>aidB</italic>). Additional SOS response inactivation (&#x00394;<italic>recA</italic>) was conducted by P1 phage transduction. All mutants were subjected to antimicrobial susceptibility testing, growth curve analysis, survival and evolution assays. To validate the relevance of these findings, experiments were also performed in a quinolone-resistant <italic>E. coli</italic> ST131 clinical isolate.</p></sec><sec id="sec3"><title>Results and discussion</title><p>Overall, no significant differences or only moderate increases in susceptibility were observed in the single mutants, with &#x00394;<italic>fumC</italic> and &#x00394;<italic>aidB</italic> mutants showing the highest susceptibility. To enhance this effect, these genes were then inactivated in combination with the SOS response by constructing &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> and &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic> mutants. These combinations exhibited significant differences in susceptibility to various antimicrobials, particularly cephalosporins and quinolones, and especially in the &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> strain. To further assess these results, we constructed an <italic>E. coli</italic> ST131 &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> mutant, in which a similar trend was observed. Together, these findings suggest that co-targeting the SOS response together with fumarases or the adaptive response could enhance the effectiveness of antibiotics against <italic>E. coli</italic>, potentially leading to new therapeutic strategies.</p></sec></abstract><kwd-group><kwd>antibiotic stress</kwd><kwd>resistance reversion</kwd><kwd>DNA damage response</kwd><kwd>fumarases</kwd><kwd>adaptive response</kwd><kwd>SOS response</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project &#x0201c;PI23/00678&#x0201d; and co-funded by the European Union. Marina Murillo-Torres is supported by a predoctoral fellowship from the Andalusian Government (call 2021, grant number PREDOC_00923), funded by the Consejer&#x000ed;a de Transformaci&#x000f3;n Econ&#x000f3;mica, Industria, Conocimiento y Universidades; Sara Diaz-Diaz is supported by a PFIS fellowship from the Instituto de Salud Carlos III (grant number FI18/00086), co-funded by ESF &#x0201c;Investing in your future&#x0201d;; Mar&#x000ed;a Romero-Mu&#x000f1;oz is supported by the Fondo Social Europeo (contract number EJ5-091) (Programa Iniciativa de Empleo Juvenil, University of Seville); Esther Recacha is supported by a Juan Rod&#x000e9;s fellowship from the Instituto de Salud Carlos III (grant number JR21/00030), co-funded by ESF &#x0201c;Investing in your future&#x0201d;.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="0"/><equation-count count="0"/><ref-count count="50"/><page-count count="11"/><word-count count="8701"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Antimicrobials, Resistance and Chemotherapy</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec4"><label>1</label><title>Introduction</title><p>Antibiotic resistance has emerged as a significant challenge to human health in recent decades. The widespread and often inappropriate use of antibiotics has accelerated the continous evolution of diverse resistance mechanisms, enabling bacteria to evade the effects of these drugs (<xref rid="ref9" ref-type="bibr">Cook and Wright, 2022</xref>). A better understanding of the molecular responses triggered in bacteria under antibiotic pressure is essential to address this situation. Such insights would help to identify new bacterial targets for the development of novel antimicrobial compounds, as well as the optimisation of existing antibiotic therapies (<xref rid="ref3" ref-type="bibr">Baker et al., 2018</xref>; <xref rid="ref6" ref-type="bibr">Bl&#x000e1;zquez et al., 2018</xref>; <xref rid="ref42" ref-type="bibr">Stokes et al., 2019</xref>).</p><p>Antibiotics typically inhibit essential cellular processes, including DNA replication, transcription, protein translation and cell wall synthesis (<xref rid="ref20" ref-type="bibr">Halawa et al., 2024</xref>). These processes impose a significant energy demand on the bacterium, and thus, their disruption leads to imbalance in metabolic homeostasis. Following the interaction between the antibiotic and the primary target, a series of multi-level processes occur downstream that ultimately contribute to bacterial death (<xref rid="ref49" ref-type="bibr">Yang et al., 2017</xref>; <xref rid="ref42" ref-type="bibr">Stokes et al., 2019</xref>). In the case of bactericidal antibiotics (<italic>&#x003b2;</italic>-lactams, quinolones or aminoglycosides), bacteria typically exhibit increased tricarboxylic acid cycle (TCA) activity. This results in elevated aerobic respiration rates and the accumulation of reactive oxygen species (ROS), which damage DNA, lipids and proteins (<xref rid="ref4" ref-type="bibr">Belenky et al., 2015</xref>; <xref rid="ref27" ref-type="bibr">Liu et al., 2019</xref>).</p><p>To mitigate antibiotic-induced stress, bacteria have evolved a variety of defence mechanisms. The main pathway to counteract DNA damage is the SOS response, a coordinated pathway that involves several genes for nucleotide excision repair, error-prone repair synthesis and homologous recombination (<xref rid="ref30" ref-type="bibr">Maslowska et al., 2019</xref>). The SOS response is activated in the presence of single-strand DNA, which promotes the co-protease activity of RecA. RecA then stimulates the cleavage of the SOS transcriptional repressor LexA, which triggers induction of the SOS regulon. Even at sub-lethal concentrations, bactericidal antibiotics induce DNA damage, thereby inducing the SOS response and eventually increasing bacterial tolerance to antibiotic stress (<xref rid="ref38" ref-type="bibr">Shapiro, 2015</xref>; <xref rid="ref6" ref-type="bibr">Bl&#x000e1;zquez et al., 2018</xref>; <xref rid="ref31" ref-type="bibr">Memar et al., 2020</xref>). Hence, inhibition of the SOS response has been proposed as an adjuvant strategy to enhance antibiotic efficacy and prevent the evolution of resistance in different bacteria. Various works have reported improvements on bacterial susceptibility to antibiotics by inactivating <italic>recA</italic>, both in laboratory and clinical strains (<xref rid="ref34" ref-type="bibr">Recacha et al., 2017</xref>; <xref rid="ref10" ref-type="bibr">Crane et al., 2021</xref>; <xref rid="ref29" ref-type="bibr">Machuca et al., 2021</xref>; <xref rid="ref25" ref-type="bibr">Ledger et al., 2023</xref>).</p><p>The adaptive response (Ada response) is another important mechanism to counteract DNA damage. This pathway is primarily engaged in the repair of alkylated nucleotides, including N<sup>3</sup>-methyladenine (3meA) and O<sup>6</sup>-methylguanine (O<sup>6</sup>meG) (<xref rid="ref32" ref-type="bibr">Mielecki and Grzesiuk, 2014</xref>; <xref rid="ref33" ref-type="bibr">Mielecki et al., 2015</xref>). These base lesions, often generated by environmental alkylating agents but also by products of cellular metabolism, are highly cytotoxic. In <italic>E. coli</italic>, the adaptive response involves four specific proteins for the repair of different types of lesions: Ada (transcriptional activator), AlkB (dioxygenase), AlkA (DNA glycosylase) and AidB (dehydrogenase) (<xref rid="ref32" ref-type="bibr">Mielecki and Grzesiuk, 2014</xref>; <xref rid="ref33" ref-type="bibr">Mielecki et al., 2015</xref>). Interestingly, AlkB activity is modulated by the TCA cycle metabolites <italic>&#x003b1;</italic>-ketoglutarate, fumarate and succinate (<xref rid="ref39" ref-type="bibr">Silas et al., 2021</xref>). Fumarase enzymes catalyse the reversible hydration of fumarate to malate in the TCA cycle and regulate the local concentrations of these metabolites, thereby signaling the DNA damage response. <italic>E. coli</italic> possesses three fumarases: FumA, FumB (class-I fumarases involved in both the TCA cycle and the DNA damage response) and FumC (a class-II fumarase primarily involved in the TCA cycle but capable of mediating the DNA damage response in the absence of other fumarases). Structurally, class-I fumarases are characterized by the presence of a ROS-sensitive catayltic Fe-S cluster, while Class-II fumarases lack this cluster (<xref rid="ref48" ref-type="bibr">Woods et al., 1988</xref>; <xref rid="ref44" ref-type="bibr">Ueda et al., 1991</xref>; <xref rid="ref18" ref-type="bibr">Flint et al., 1993</xref>). Strains lacking these enzymes show compromised survival when exposed to the genotoxic compound methyl methanesulfonate (MMS) (<xref rid="ref39" ref-type="bibr">Silas et al., 2021</xref>).</p><p>In this study, we investigated whether fumarases and the adaptive response also provide protection against antibiotic-induced genotoxicity. Given their roles in the response to DNA damage and central metabolism, we hypothesised that targeting these pathways would also influence the bacterial response to antibiotics. In accordance with this hypothesis, previous authors have reported that fumarase and adaptive response deficiency in <italic>E. coli</italic> leads to enhanced susceptibility to certain antibiotics (<xref rid="ref24" ref-type="bibr">Kang et al., 2012</xref>; <xref rid="ref22" ref-type="bibr">Himpsl et al., 2020</xref>). In this study, we initially screened the effect of a large number of antibiotics on <italic>E. coli</italic> BW25113 mutants lacking fumarase (&#x00394;<italic>fumA</italic>, &#x00394;<italic>fumB</italic>, &#x00394;<italic>fumC</italic>) and adaptive response genes (&#x00394;<italic>alkA</italic>, &#x00394;<italic>alkB,</italic> &#x00394;<italic>aidB</italic>). The results showed that inactivation of these genes had a minimal effect on antibiotic susceptibility. The potential of combining the inactivation of these genes with the inactivation of the SOS response was then investigated, since targeting the SOS response in combination with other stress pathways has previously resulted in enhanced sensitisation of the strain BW25113 (<xref rid="ref14" ref-type="bibr">Diaz-Diaz et al., 2021</xref>, <xref rid="ref13" ref-type="bibr">2022</xref>, <xref rid="ref15" ref-type="bibr">2023</xref>). Here, double inactivation of the SOS response with either fumarases (&#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic>) or else the adaptive response (&#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic>) lead to enhanced sensitisation compared to single SOS inactivation, particularly to quinolones and certain <italic>&#x003b2;</italic>-lactams. This phenomenon was more pronounced in the &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> strain. The findings were assessed in terms of bacterial growth, survival and evolvability. Finally, we further evaluated the impact of <italic>fumC</italic>/<italic>recA</italic> inactivation in a clinical isolate of <italic>E. coli</italic> ST131, where a similar trend towards enhanced antibiotic susceptibility was again observed.</p></sec><sec sec-type="materials|methods" id="sec5"><label>2</label><title>Materials and methods</title><sec id="sec6"><label>2.1</label><title>Bacterial strains</title><p>Wild-type <italic>E. coli</italic> BW25113 and single-gene inactivation mutants (&#x02206;<italic>fumA</italic>, &#x02206;<italic>fumB</italic>, &#x02206;<italic>fumC</italic>, &#x02206;<italic>alkA</italic>, &#x02206;a<italic>lkB</italic>, &#x02206;<italic>aidB,</italic> &#x02206;<italic>recA</italic>) were selected from the KEIO collection (<xref rid="SM1" ref-type="supplementary-material">Supplementary Table S1</xref>) (<xref rid="ref2" ref-type="bibr">Baba et al., 2006</xref>). Double-gene mutants of <italic>E. coli</italic> BW25113 (&#x02206;<italic>fumC/</italic>&#x02206;<italic>recA</italic>, &#x02206;<italic>aidB/</italic>&#x02206;<italic>recA</italic>) were generated by P1vir phage transduction after removing the kanamycin cassette using plasmid pCP20 (<xref rid="ref11" ref-type="bibr">Datsenko and Wanner, 2000</xref>; <xref rid="ref43" ref-type="bibr">Thomason et al., 2007</xref>). The <italic>E. coli</italic> clinical isolate FI20 was provided by the Andalusian Reference Laboratory for Molecular Typing of Nosocomial Pathogens (PIRASOA programme). This isolate belongs to the high-risk clone ST131 and exhibits a low-level quinolone resistance (LLQR) phenotype, as defined by the CLSI reference guidelines (<xref rid="ref28" ref-type="bibr">L&#x000f3;pez-Cerero et al., 2013</xref>). <italic>E. coli</italic> FI20 single-gene inactivation mutants (&#x02206;<italic>fumC</italic>, &#x02206;<italic>recA</italic>) were constructed using a modified version of the Datsenko and Warner method (<xref rid="ref11" ref-type="bibr">Datsenko and Wanner, 2000</xref>; <xref rid="ref29" ref-type="bibr">Machuca et al., 2021</xref>) (<xref rid="SM1" ref-type="supplementary-material">Supplementary Table S2</xref>). In brief, a kanamycin resistance cassette was amplified by PCR using the pKD4 vector as a template and a pair of specific primers containing 5&#x02032; extensions homologous to the upstream/downstream sequences of the genes to be inactivated. The primers used were H1-fumC-P1 and H2-fumC-P2 for <italic>fumC</italic> replacement, and H1-recA-P1 and H2-fumC-P2 for <italic>recA</italic> replacement (<xref rid="SM1" ref-type="supplementary-material">Supplementary Table S2</xref>). The resulting amplicons were used to replace the genomic wild-type genes on the FI20 chromosome by homologous recombination using the Red helper plasmid pKOBEG (<xref rid="ref7" ref-type="bibr">Chaveroche et al., 2000</xref>), which encodes an arabinose-inducible recombinase. The resulting gene inactivations were confirmed by PCR and Sanger sequencing.</p></sec><sec id="sec7"><label>2.2</label><title>Antimicrobial susceptibility screening</title><p>For antimicrobial susceptibility testing of all strains, disc diffusion (Oxoid) was used as the reference method, according to the CLSI guidelines (Performance Standards for Antimicrobial Susceptibility Testing, 34th Edition. CLSI Guideline M100) (<xref rid="ref8" ref-type="bibr">CLSI, n.d.</xref>). A 0.5 McFarland suspension (10<sup>8</sup>&#x0202f;CFU/mL) of each strain was plated on Mueller-Hinton Agar II (MHA) (Becton, Dickinson and Company), to which relevant antibiotic discs were added. The results were read after overnight incubation at 37&#x000b0;C. The panel of antimicrobial discs consisted of 26 antimicrobial agents and included ampicillin (AMP, 10&#x0202f;&#x003bc;g), amoxicillin (AML, 25&#x0202f;&#x003bc;g), amoxicillin-clavulanic acid (AMC, 30&#x0202f;&#x003bc;g), piperacillin (PRL, 30&#x0202f;&#x003bc;g), piperacillin-tazobactam (TZP, 36&#x0202f;&#x003bc;g), temocillin (TEM, 30&#x0202f;&#x003bc;g), cefepime (FEP, 30&#x0202f;&#x003bc;g), cefotaxime (CTX, 5&#x0202f;&#x003bc;g), ceftazidime (CAZ, 10&#x0202f;&#x003bc;g), ceftazidime-avibactam (CZA, 50&#x0202f;&#x003bc;g), ertapenem (ETP, 10&#x0202f;&#x003bc;g), imipenem (IPM, 10&#x0202f;&#x003bc;g), meropenem (MEM, 10&#x0202f;&#x003bc;g), ciprofloxacin (CIP, 5&#x0202f;&#x003bc;g), levofloxacin (LEV, 5&#x0202f;&#x003bc;g), norfloxacin (NOR, 10&#x0202f;&#x003bc;g), nalidixic acid (NA, 30&#x0202f;&#x003bc;g), amikacin (AK, 30&#x0202f;&#x003bc;g), gentamicin (CN, 10&#x0202f;&#x003bc;g), tobramycin (TOB, 10&#x0202f;&#x003bc;g), chloramphenicol (C, 30&#x0202f;&#x003bc;g), fosfomycin (FOT, 200&#x0202f;&#x003bc;g), rifampicin (RD, 5&#x0202f;&#x003bc;g), trimethoprim (W, 1.25&#x0202f;&#x003bc;g), trimethoprim-sulfamethoxazole (SXT, 25&#x0202f;&#x003bc;g) and tetracycline (TE, 30&#x0202f;&#x003bc;g). Callipers were used to measure the diameter of the inhibition halo (in mm) and to calculate the halo difference between each mutant and its wild-type strain (<italic>E. coli</italic> BW25113 or <italic>E. coli</italic> FI20). The experiment was repeated twice, and the largest halo differences obtained for each antimicrobial/strain combination were noted.</p><p>Among the antimicrobials tested by disc diffusion, a <italic>&#x003b2;</italic>-lactam (cefepime) and a quinolone (ciprofloxacin) were selected to determine the Minimum Inhibitory Concentration (MIC) of these antibiotics for all the strains. Gradient strips (Liofilchem) were utilised in accordance with the manufacturer&#x02019;s instructions. The result was assessed in triplicate for each antimicrobial/strain combination.</p></sec><sec id="sec8"><label>2.3</label><title>Bacterial growth curves</title><p>Bacterial growth curves of BW25113 and FI20 were performed to assess the effect of antibiotic pressure in fumarase-, adaptive response- and SOS response-deficient backgrounds. Transparent 96-well flat-bottom plates (Nunclon Delta Surface, Thermo Scientific, MA) were prepared with 200&#x0202f;&#x003bc;L of Luria-Bertani Broth (LBB) (Invitrogen), supplemented with and without sublethal concentrations of ciprofloxacin (Sigma Aldrich) or cefepime (Santa Cruz Biotechnology). Different antibiotic concentrations were used to detect different growth patterns between the WT strain and the isogenic mutants: 0.004&#x0202f;&#x003bc;g/mL CIP (1/2 x MIC of BW25113) in <xref rid="fig1" ref-type="fig">Figure 1C</xref>; 0.002&#x0202f;&#x003bc;g/mL CIP (1/4 x MIC of BW25113 WT) or 0.016&#x0202f;&#x003bc;g/mL FEP (1/2 x MIC of BW25113 WT) in <xref rid="fig2" ref-type="fig">Figure 2C</xref>; and 0.25&#x0202f;&#x003bc;g/mL CIP (1/3 x MIC of FI20 WT) or 0.031&#x0202f;&#x003bc;g/mL FEP (1/4 x MIC of FI20 WT) in <xref rid="fig3" ref-type="fig">Figure 3C</xref>. Next, the LBB 96-well plates were inoculated with 5&#x000d7;10<sup>3</sup> CFU/mL bacteria previously grown to exponential phase, and bacterial growth was monitored by measuring the OD<sub>595nm</sub> of each well every hour for 24&#x0202f;h at 37&#x000b0;C using an Infinite200 PRO plate reader (Tecan, Madrid, Spain). Two independent assays with at least three replicates were performed for all conditions evaluated. Finally, the Area Under the Curve (AUC) was calculated using the Growthcurver R package (<xref rid="ref41" ref-type="bibr">Sprouffske and Wagner, 2016</xref>).</p><fig position="float" id="fig1"><label>Figure 1</label><caption><p>Inactivation of fumarases and the adaptive response resulted in no or slightly increased antimicrobial susceptibility. <bold>(A)</bold> Susceptibility screening by disc diffusion test on <italic>E. coli</italic> BW25113 isogenic mutants with different inactivated fumarases or adaptive response genes. The results are presented as a heatmap showing the differences in inhibition halo diameter (mm) of each mutant versus the BW25113 wild-type (WT) strain. The abbreviations correspond to different antimicrobial discs with the indicated amounts of each (in &#x003bc;g). <bold>(B)</bold> Minimum Inhibitory Concentrations (MIC) of ciprofloxacin (CIP) (blue column) and cefepime (FEP) (red column) determined by E-test for the WT and each BW25113 mutant. Values were determined in triplicate. <bold>(C)</bold> Growth curves of BW25113 WT, &#x00394;<italic>fumC</italic> and &#x00394;<italic>aidB</italic> over 24&#x0202f;h in the absence of antibiotics (<italic>left</italic>) and in the presence of subinhibitory concentrations of ciprofloxacin (0.004&#x0202f;&#x003bc;g/mL, equivalent to 1/2 x MIC of the WT strain) (<italic>right</italic>). Data are the mean of three independent measurements from a representative replicate.</p></caption><graphic xlink:href="fmicb-16-1570764-g001" position="float"/></fig><fig position="float" id="fig2"><label>Figure 2</label><caption><p>Combined inactivation of the SOS response (<italic>recA</italic>) with fumarase (<italic>fumC</italic>) or the adaptive response (<italic>aidB</italic>) significantly enhances antibiotic susceptibility. <bold>(A)</bold> Susceptibility screening by disc diffusion test on single and double mutants of <italic>E. coli</italic> BW25513. The results are presented as a heatmap, showing the difference in inhibition halo diameter (mm) of each mutant relative to the BW25113 wild-type (WT) strain. The abbreviations correspond to different antimicrobial discs with the indicated amount of each (in &#x003bc;g). <bold>(B)</bold> Minimum Inhibitory Concentrations (MIC) of ciprofloxacin (CIP) (blue column) and cefepime (FEP) (red column) for BW25113 WT and the various mutants by E-test. Values were determined in triplicate. <bold>(C)</bold> Growth curves of all BW25113 strains over 24&#x0202f;h in the absence of antibiotics (<italic>left</italic>), in the presence of subinhibitory concentrations of ciprofloxacin (0.002&#x0202f;&#x003bc;g/mL, equivalent to 1/4 x MIC of the WT strain) (<italic>middle</italic>), and in the presence of subinhibitory concentrations of cefepime (0.016&#x0202f;&#x003bc;g/mL, equivalent to 1/2 x MIC of the WT strain) (<italic>right</italic>). Data are the mean of at least three independent measurements from one representative replicate. <bold>(D)</bold> Survival of BW25113 mutants determined by spot test. A representative replicate of the experiment is shown on the left. Serial dilutions of each strain were spotted on LB agar without antibiotic, or supplemented with ciprofloxacin (0.001&#x0202f;&#x003bc;g/mL, equivalent to 1/8 x MIC of the WT strain) or cefepime (0.008&#x0202f;&#x003bc;g/mL, equivalent to 1/4 x MIC of the WT strain). On the right, mean survival percentage of each mutant under antibiotic pressure (ciprofloxacin above, cefepime below) relative to the untreated control. Data are the mean of at least four independent quantitative measurements. Hatched columns correspond to &#x00394;<italic>recA</italic> mutants. Significant <italic>p</italic> values are recorded (ns, not significant; ***, <italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.001; ****, <italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.0001). <bold>(E)</bold> Evolution capacity of each BW25113 strain without antibiotic pressure (<italic>left</italic>) and in the presence of daily increases of ciprofloxacin (<italic>middle</italic>) and cefepime (<italic>right</italic>) over several days. The dashed vertical line represents the MIC of the WT and the double mutants for each antibiotic.</p></caption><graphic xlink:href="fmicb-16-1570764-g002" position="float"/></fig><fig position="float" id="fig3"><label>Figure 3</label><caption><p>Inactivation of <italic>fumC</italic> and/or <italic>recA</italic> enhances antimicrobial susceptibility in a LLQR ST131 isolate. <bold>(A)</bold> Susceptibility screening by disc diffusion test on the <italic>E. coli</italic> FI20 clinical isolate and its isogenic mutants. The results are displayed as a heatmap, showing the difference in diameter of the inhibition halo (mm) of each mutant versus the FI20 WT strain. The abbreviations correspond to different antimicrobial discs with the indicated amounts (in &#x003bc;g). <bold>(B)</bold> Minimum Inhibitory Concentrations (MIC) of ciprofloxacin (CIP) (blue column) and cefepime (FEP) (red column) for the FI20 WT strain and each mutant by E-test. Values were determined in triplicate. <bold>(C)</bold> Growth curves of all strains over 24&#x0202f;h in the absence of antibiotics (<italic>left</italic>); in the presence of subinhibitory concentrations of ciprofloxacin (0.25&#x0202f;&#x003bc;g/mL, equivalent to 1/3 x MIC of the FI20 WT strain) (<italic>middle</italic>); and in the presence of subinhibitory concentrations of cefepime (0.031&#x0202f;&#x003bc;g/mL, equivalent to 1/4 x MIC of the FI20 WT strain) (<italic>right</italic>). Data are the mean of at least three independent measurements from one representative replicate. <bold>(D)</bold> Survival of FI20 isogenic strains determined by spot test. Serial dilutions of each strain were spotted on LB agar without or with ciprofloxacin (~0.2&#x0202f;&#x003bc;g/mL, equivalent to 1/4 x MIC of the FI20 WT strain) and cefepime (0.031&#x0202f;&#x003bc;g/mL, equivalent to 1/4 x MIC of the FI20 WT strain). A representative replicate of the experiment is shown.</p></caption><graphic xlink:href="fmicb-16-1570764-g003" position="float"/></fig></sec><sec id="sec9"><label>2.4</label><title>Spot test</title><p>Survival of BW25113 and FI20 strains in the presence of antibiotics was evaluated by spot test. 7&#x0202f;&#x003bc;L of serially diluted 0.5 McFarland suspensions (10<sup>8</sup>&#x0202f;CFU/mL) of all strains were spotted on LB Agar (LBA) (Invitrogen) plates containing subinhibitory concentrations of ciprofloxacin or cefepime (1/8 to 1/2 x MIC relative to the wild-type strain of each isogenic group). Only the concentration that produced the most pronounced differences between the strains is shown. After incubation for 20&#x0202f;h at 37&#x000b0;C, the spots were checked for growth and compared with those on a control plate without antimicrobial agent. To quantify bacterial survival, colony counts were performed only when the colonies were large enough to be seen clearly. Bacterial survival was calculated as the percentage of the population that survived in the presence of antibiotics relative to survival in the control without antibiotics. All conditions were tested in at least three independent assays with two replicates each.</p></sec><sec id="sec10"><label>2.5</label><title>Experimental evolution of antibiotic resistance</title><p>The ability of <italic>E. coli</italic> BW25113 wild-type and mutant strains to evolve antibiotic resistance was tested using a method that maximises the chances of a population acquiring resistance mutations (<xref rid="ref17" ref-type="bibr">Escudero et al., 2018</xref>). The experiment compared the behaviour of different strains exposed to gradually increasing concentrations of antibiotics over several days. Briefly, 2&#x0202f;&#x003bc;L of overnight-grown bacteria were inoculated into 96-well plates (Nunclon Delta Surface, Thermo Scientific, MA) containing 198&#x0202f;&#x003bc;L of LBB supplemented with 6.25&#x000d7;10<sup>&#x02212;5</sup> &#x003bc;g/mL of ciprofloxacin or 0.001&#x0202f;&#x003bc;g/mL of cefepime. These concentrations corresponded to 1/16 x MIC of the strain with the lowest MIC, determined by the broth microdilution method (data not shown), following to the CLSI guidelines (<xref rid="ref8" ref-type="bibr">CLSI, n.d.</xref>). After overnight culturing at 37&#x000b0;C without shaking, the turbidity of the wells was quantified by measuring absorbance values at OD<sub>595nm</sub> using an Infinite200 PRO plate reader (Tecan, Madrid, Spain). Next, 2&#x0202f;&#x003bc;L of the grown culture was transferred to another 96-well plate with a double concentration of antibiotic and incubated again until the following day. This process was repeated daily until OD<sub>595nm</sub> values were below 0.1, indicating population extinction. Parallel control cultures were performed by propagating the selected strains under identical conditions but without antibiotics. The experiment included a minimum of 16 biological replicates for each strain.</p></sec><sec id="sec11"><label>2.6</label><title>Statistical analysis</title><p>All statistical analyses were performed using GraphPad Prism 8 software. Student&#x02019;s <italic>t-tests</italic> were used to compare two groups. The log-rank (Mantel-Cox) test was used to compare evolution curves in the experimental evolution assay. Differences were considered significant when <italic>p</italic>-values were &#x0003c;0.05.</p></sec></sec><sec sec-type="results" id="sec12"><label>3</label><title>Results</title><sec id="sec13"><label>3.1</label><title>Inactivation of fumarases or the adaptive response resulted in null or only slightly increased antimicrobial susceptibility</title><p>To identify potential genes involved in antimicrobial sensitisation, we evaluated the response to antimicrobial agents of various <italic>E. coli</italic> BW25113 mutants lacking fumarases (&#x00394;<italic>fumA</italic>, &#x00394;<italic>fumB</italic>, &#x00394;<italic>fumC</italic>) or adaptive response (&#x00394;<italic>alkA</italic>, &#x00394;<italic>alkB</italic>, &#x00394;<italic>aidB</italic>) genes (<xref rid="SM1" ref-type="supplementary-material">Supplementary Table S1</xref>). As starting point, all mutants were tested by disc diffusion assay for susceptibility to 26 antimicrobials. Compared to the wild-type strain, the mutants exhibited moderate or no change in sensitisation (<xref rid="fig1" ref-type="fig">Figure 1A</xref>). Differences in inhibition zone diameter were up to 6&#x0202f;mm, mostly for penicillins, cephalosporins and quinolones. Notably, various mutants were more susceptible to cefepime, with the largest halo difference observed for &#x00394;<italic>fumC</italic> (6&#x0202f;mm). After applying a cut-off of &#x02265; 3&#x0202f;mm difference, &#x00394;<italic>fumC</italic> was identified as the strain most sensitised to the greatest number of antimicrobial agents, followed by &#x00394;<italic>aidB</italic>. Inhibition zone differences lower than 3&#x0202f;mm were not considered relevant.</p><p>To determine the effect of these gene inactivations on MIC, gradient strip assays were performed for a quinolone and a <italic>&#x003b2;</italic>-lactam. Ciprofloxacin and cefepime were selected based on the inhibition zone differences obtained by disc diffusion. No significant changes in susceptibility were observed for either of these antibiotics (<xref rid="fig1" ref-type="fig">Figure 1B</xref>). In terms of growth, exposure to 0.004&#x0202f;&#x003bc;g/mL of ciprofloxacin (1/2 x MIC of wild-type BW25113) delayed the growth of &#x00394;<italic>fumC</italic> only slightly, and had no effect on the growth dynamics of &#x00394;<italic>aidB</italic> (<xref rid="fig1" ref-type="fig">Figure 1C</xref>, <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S1</xref>). Taken together, these data suggest that inactivation of fumarase and adaptive response genes on their own have little influence on antibiotic resistance in <italic>E. coli</italic>.</p></sec><sec id="sec14"><label>3.2</label><title>Combined inactivation of fumarases or the adaptive response together with the SOS response significantly improved overall antimicrobial efficacy</title><p>Although targeting fumarases or adaptive response genes alone had little or no effect on antibiotic susceptibility, the hypothesis was considered that simultaneous inactivation of different DNA damage responses would have a greater effect. Therefore, we combined the inactivation of fumarases and adaptive response genes with the inactivation of the SOS response (&#x00394;<italic>recA</italic>). As the <italic>fumC</italic> and <italic>aidB</italic> inactivations showed slightly higher increments of susceptibility (<xref rid="fig1" ref-type="fig">Figure 1A</xref>), these genes were selected to construct the double mutant strains: &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> and &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic> (<xref rid="SM1" ref-type="supplementary-material">Supplementary Table S1</xref>).</p><p>Antibiotic disc diffusion assays were performed to test the phenotype of &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> and &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic>. As expected, &#x00394;<italic>recA</italic> exhibited reduced resistance to quinolones, with inhibition halo diameters differing by up to 11&#x0202f;mm compared to the wild-type (<xref rid="fig2" ref-type="fig">Figure 2A</xref>). Beyond that, the double mutants displayed enhanced susceptibility, particularly to quinolones. The largest differences were observed for ciprofloxacin (16&#x0202f;mm for &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic>; 13&#x0202f;mm for &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic>) and levofloxacin (18 and 12&#x0202f;mm, respectively) (<xref rid="fig2" ref-type="fig">Figure 2A</xref>, <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S2</xref>). Susceptibility to penicillins and cephalosporins was also significantly increased, particularly for cefepime (13&#x0202f;mm for &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic>; 15&#x0202f;mm for &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic>) and cefotaxime (15 and 9&#x0202f;mm, respectively). It should also be noted that inactivation of <italic>recA</italic> alone did not alter susceptibility to certain antimicrobials, whereas simultaneous inactivation of the pathways did, e.g., amoxicillin&#x02013;clavulanic acid (7&#x0202f;mm for &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic>; 8&#x0202f;mm for &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic>), temocillin (9&#x0202f;mm for &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic>; 7&#x0202f;mm for &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic>) and chloramphenicol (6&#x0202f;mm for &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic>; 7&#x0202f;mm for &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic>).</p><p>To confirm these data, ciprofloxacin and cefepime gradient strip assays were again performed on the mutants. The antimicrobial activity of ciprofloxacin was enhanced against &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> and &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic>, with a MIC value lower than 0.002&#x0202f;&#x003bc;g/mL. This is a more than two-fold reduction compared to the MIC of 0.002&#x0202f;&#x003bc;g/mL observed against the &#x00394;<italic>recA</italic> mutant (<xref rid="fig2" ref-type="fig">Figure 2B</xref>, <italic>left</italic>). However, no reduction in cefepime MICs was detected in the double mutants or in &#x00394;<italic>recA</italic>, compared to the wild-type (<xref rid="fig2" ref-type="fig">Figure 2B</xref>, <italic>right</italic>).</p></sec><sec id="sec15"><label>3.3</label><title>Double inactivation of fumarases or the adaptive response together with the SOS response affects bacterial growth and survival under ciprofloxacin and cefepime pressure</title><p>To understand the effect of combined inactivation of <italic>fumC</italic>, <italic>aidB</italic> and <italic>recA</italic> under antibiotic exposure, we analysed the ability of double mutants to grow at subinhibitory concentrations of ciprofloxacin and cefepime. In the absence of antibiotics, all <italic>recA</italic>-deficient strains reached similar OD values after 24&#x0202f;h (<xref rid="fig2" ref-type="fig">Figure 2C</xref>, <italic>left</italic>; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S3</xref>), although the &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> mutant exhibited delayed growth during the exponential phase. At a ciprofloxacin concentration of 0.002&#x0202f;&#x003bc;g/mL (1/4 x MIC of wild-type BW25113) (<xref rid="fig2" ref-type="fig">Figure 2C</xref>, <italic>middle</italic>), the ODs of all <italic>recA</italic> mutants decreased considerably. This phenomenon was particularly pronounced for &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> and &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic>. To illustrate, while the mean optical density of &#x00394;<italic>recA</italic> reached 0.41 after 20&#x0202f;h of growth, the OD values of &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> and &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic> decreased significantly further to 0.16 and 0.25, respectively (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.0001) (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S3</xref>). On the other hand, at 0.016&#x0202f;&#x003bc;g/mL of cefepime (1/2 x MIC of wild-type BW25113), all strains showed reduced growth rates. As above, &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> and &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic> showed markedly diminished growth compared to &#x00394;<italic>recA</italic>, which showed enhanced growth under these conditions (<xref rid="fig2" ref-type="fig">Figure 2C</xref>, <italic>right</italic>). While the mean OD of &#x00394;<italic>recA</italic> reached 0.36 after 20&#x0202f;h, the values for &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> and &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic> were significantly reduced to 0.09 and 0.13, respectively (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.0001) (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S3</xref>). AUC comparisons between &#x00394;<italic>recA</italic> and &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> and &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic> also showed significantly decreased bacterial growth in the presence of the two antibiotics (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.05).</p><p>Following this line, spot tests were used to determine the survival of the different strains to antibiotics (<xref rid="fig2" ref-type="fig">Figure 2D</xref>). Without antibiotic pressure, all strains showed similar survival (<xref rid="fig2" ref-type="fig">Figure 2D</xref><italic>, left</italic>). At 0.001&#x0202f;&#x003bc;g/mL of ciprofloxacin (1/8 x MIC of BW25113 wild-type), survival of wild-type, &#x00394;<italic>fumC</italic> and &#x00394;<italic>aidB</italic> was unaffected, whereas <italic>recA</italic> strains showed increased sensitivity (<xref rid="fig2" ref-type="fig">Figure 2D</xref><italic>, left</italic>). Although a decrease in colony size was observed for &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic>, no significant differences between &#x00394;<italic>recA</italic>, &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> or &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic> colony counts (<italic>p</italic>&#x0202f;&#x0003e;&#x0202f;0.05) were found (<xref rid="fig2" ref-type="fig">Figure 2D</xref>, <italic>top right graph</italic>). In contrast, exposure to 0.008&#x0202f;&#x003bc;g/mL of cefepime (1/4 x MIC of BW25113 wild-type) did not affect the survival of &#x00394;<italic>recA</italic>, which was similar to that of the wild-type and the other single mutants (<xref rid="fig2" ref-type="fig">Figure 2D</xref><italic>, left</italic>). Interestingly, in this case, the survival of &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> and &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic> was negatively affected, in contrast to &#x00394;<italic>recA</italic>. While the mean survival of &#x00394;<italic>recA</italic> was 84%, the percentages for the two double mutants were significantly lower: 37% for &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.001) and 21% for &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic> (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.0001) (<xref rid="fig2" ref-type="fig">Figure 2D</xref>, <italic>bottom right graph</italic>).</p></sec><sec id="sec16"><label>3.4</label><title>Impact of the inactivation of <italic>fumC</italic>, <italic>aidB</italic> and <italic>recA</italic> in BW25113 on the evolution of acquired resistance to ciprofloxacin and cefepime</title><p><italic>In vitro</italic> evolution experiments were carried out to compare the ability of each strain to acquire resistance in the presence of antibiotics. In these experiments, the concentrations of ciprofloxacin or cefepime were doubled daily to maximise the probability of acquiring resistance mutations. In the absence of antibiotics, no differences between the strains were observed (<xref rid="fig2" ref-type="fig">Figure 2E</xref>, <italic>left</italic>).</p><p>In the evolution experiment with ciprofloxacin, we started from 6.25&#x000d7;10<sup>&#x02212;5</sup> &#x003bc;g/mL. With increasing ciprofloxacin concentration, a general decrease in growth was observed for &#x00394;<italic>recA</italic> strains (no growth at 0.008&#x0202f;&#x003bc;g/mL &#x02013; 0.25&#x0202f;&#x003bc;g/mL) in contrast to BW25113 wild-type, &#x00394;<italic>fumC</italic> and &#x00394;<italic>aidB</italic> (no growth at 1&#x0202f;&#x003bc;g/mL&#x0202f;&#x02212;&#x0202f;2&#x0202f;&#x003bc;g/mL) (<xref rid="fig2" ref-type="fig">Figure 2E</xref>, <italic>middle</italic>). A log-rank test revealed that the differences between these two groups were statistically significant (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.0001). However, no significant differences were found when comparing the wild-type with &#x00394;<italic>fumC</italic> or &#x00394;<italic>aidB</italic>, nor between &#x00394;<italic>recA</italic> and &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> or &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic>. Furthermore, on day 8, when the strains were exposed to the wild-type MIC, the growth capacity of &#x00394;<italic>recA</italic> strains was below 50%, whereas the percentage was the same or higher in BW25113 wild-type, &#x00394;<italic>fumC</italic> and &#x00394;<italic>aidB</italic>.</p><p>In the evolution experiment with cefepime, we started from 0.001&#x0202f;&#x003bc;g/mL. With increasing cefepime concentration, all strains survived at concentrations above the MIC of the wild-type strain (0.032&#x0202f;&#x003bc;g/mL), but no growth was detected at concentrations between 0.5&#x0202f;&#x003bc;g/mL and 1&#x0202f;&#x003bc;g/mL (<xref rid="fig2" ref-type="fig">Figure 2E</xref>, <italic>right</italic>). As expected, a log-rank test showed significant differences between the wild-type and &#x00394;<italic>recA</italic> (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.01). Neither inactivation of <italic>fumC</italic> alone nor combined inactivation with <italic>recA</italic> altered the adaptability of BW25113, whereas a markedly significant difference was found when the wild-type was compared to &#x00394;<italic>aidB</italic> and &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic> (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.0001). Significant differences were also found between &#x00394;<italic>recA</italic> and &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic> (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.001), indicating that the impact of <italic>aidB</italic> inactivation can be enhanced by also inactivating the SOS response.</p></sec><sec id="sec17"><label>3.5</label><title>Combined inactivation of <italic>fumC</italic> and <italic>recA</italic> substantially restores the susceptibility of a high-risk clone with low-level clinical resistance</title><p>Since joint inactivation of <italic>fumC</italic>, <italic>aidB</italic> and <italic>recA</italic> showed increased sensitisation in a laboratory strain of <italic>E. coli</italic>, we decided to test this strategy on the FI20 clinical isolate (ST131 clone), which is a strain with low-level resistance to quinolones (LLQR). Having observed that the BW25113 &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> mutant was slightly more susceptible to antibiotics than &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic>, we focused on the first combination and generated FI20 &#x00394;<italic>fumC</italic>, &#x00394;<italic>recA</italic> and &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> mutants (<xref rid="SM1" ref-type="supplementary-material">Supplementary Table S1</xref>).</p><p>As above, disc diffusion screening tests were performed on the <italic>E. coli</italic> FI20 strains (<xref rid="fig3" ref-type="fig">Figure 3A</xref>). FI20 &#x00394;<italic>fumC</italic> showed a maximum halo difference of 6&#x0202f;mm, especially for aminoglycosides and miscellaneous agents. FI20 &#x00394;<italic>recA</italic> displayed increased sensitisation to quinolones. Remarkably, FI20 &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> exhibited larger zones of inhibition than FI20 &#x00394;<italic>recA</italic>. The major differences were for ampicillin (6&#x0202f;mm difference in FI20 &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic>; 1&#x0202f;mm in FI20 &#x00394;<italic>recA</italic>), cefepime (9&#x0202f;mm in FI20 &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic>; 5&#x0202f;mm in FI20 &#x00394;<italic>recA</italic>), ciprofloxacin (11&#x0202f;mm in FI20 &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic>; 7&#x0202f;mm in FI20 &#x00394;<italic>recA</italic>), fosfomycin (9&#x0202f;mm in FI20 &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic>; 3&#x0202f;mm in FI20 &#x00394;<italic>recA</italic>) and trimethoprim (8&#x0202f;mm in FI20 &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic>; 2&#x0202f;mm in FI20 &#x00394;<italic>recA</italic>) (<xref rid="fig3" ref-type="fig">Figure 3A</xref>, <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S4</xref>), among others. We then assessed these results by E-test and observed a gradual decrease in ciprofloxacin MICs from FI20 &#x00394;<italic>fumC</italic> and FI20 &#x00394;<italic>recA</italic> to FI20 &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> (<xref rid="fig3" ref-type="fig">Figure 3B</xref>, <italic>left</italic>). In contrast, no differences in cefepime MICs were observed, except for a slight decrease in F120 &#x00394;<italic>recA</italic> (<xref rid="fig3" ref-type="fig">Figure 3B</xref>, <italic>right</italic>).</p><p>With respect to bacterial growth, all strains in the untreated controls behaved in a similar way (<xref rid="fig3" ref-type="fig">Figure 3C</xref>, <italic>left</italic>). At a ciprofloxacin concentration of 0.25&#x0202f;&#x003bc;g/mL (1/3 x MIC of wild-type FI20), only FI20 &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> growth was completely inhibited (<xref rid="fig3" ref-type="fig">Figure 3C</xref>, <italic>middle</italic>). After 20&#x0202f;h of growth, the mean ODs of FI20, FI20 &#x00394;<italic>fumC</italic>, FI20 &#x00394;<italic>recA</italic> and FI20 &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> were 0.71, 0.45, 0.29 and 0.10, respectively (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S5</xref>). Significant differences were found in the ODs (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.01) and AUCs (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.001) of FI20 &#x00394;<italic>recA</italic> and FI20 &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic>. At a cefepime concentration of 0.031&#x0202f;&#x003bc;g/mL (1/4 x MIC of wild-type FI20), growth of FI20 &#x00394;<italic>recA</italic> and FI20 &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> was significantly impaired (<xref rid="fig3" ref-type="fig">Figure 3C</xref>, <italic>right</italic>). After 20&#x0202f;h, the ODs of FI20, FI20 &#x00394;<italic>fumC</italic>, FI20 &#x00394;<italic>recA</italic> and FI20 &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> were 0.37, 0.28, 0.25 and 0.14, respectively (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S5</xref>). Similarly, significant differences were found in the ODs (<italic>p</italic>&#x0202f;&#x0003c;&#x0202f;0.01) and AUCs (p&#x0202f;&#x0003c;&#x0202f;0.001) of FI20 &#x00394;<italic>recA</italic> and FI20 &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic>.</p><p>Survival of the FI20 strains was also evaluated by spot test (<xref rid="fig3" ref-type="fig">Figure 3D</xref>). Following exposure to 0.2&#x0202f;&#x003bc;g/mL ciprofloxacin (1/4 x MIC of wild-type FI20), the strains with inactivated SOS response were more susceptible than FI20 wild-type and FI20 &#x00394;<italic>fumC</italic>. Moreover, FI20 &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> was even more sensitised than the single FI20 &#x00394;<italic>recA</italic> mutant (about 10<sup>1</sup>-fold). However, exposure to 0.031&#x0202f;&#x003bc;g/mL cefepime (1/4 x MIC of wild-type FI20) did not significantly alter the survival of FI20 &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> compared to FI20 &#x00394;<italic>recA</italic> or FI20 &#x00394;<italic>fumC</italic>.</p></sec></sec><sec sec-type="discussion" id="sec18"><label>4</label><title>Discussion</title><p>Stress response mechanisms allow bacteria to adapt to and survive antibiotic pressure. These mechanisms therefore represent potential molecular targets for enhancing antibiotic activity and slowing the development of antibiotic resistance (<xref rid="ref12" ref-type="bibr">Dawan and Ahn, 2022</xref>). The aim of this study was to investigate whether a recently identified pathway that protects against genotoxic damage also provides protection against antibiotic stress (<xref rid="ref39" ref-type="bibr">Silas et al., 2021</xref>). This pathway involves the interplay between fumarases (<italic>fumA, fumB, fumC</italic>) and the adaptive response (<italic>alkA</italic>, <italic>alkB</italic>, <italic>aidB</italic>). The absence of fumarases and the adaptive response is associated with the inability of bacteria to survive in the presence of MMS, a compound that methylates DNA bases, blocking the progression of DNA polymerase or promoting the potential accumulation of miscoding nucleotides (<xref rid="ref33" ref-type="bibr">Mielecki et al., 2015</xref>). Some antibiotics also induce DNA damage and increase genomic instability (<xref rid="ref38" ref-type="bibr">Shapiro, 2015</xref>). For instance, quinolones generate double-strand DNA breaks by inhibiting DNA gyrase and topoisomerase (<xref rid="ref16" ref-type="bibr">Drlica, 1999</xref>), while other antibiotics damage DNA indirectly by increasing ROS levels, disrupting the balance of nucleotide pools or interfering with the correct translation of proteins (<xref rid="ref5" ref-type="bibr">Bl&#x000e1;zquez et al., 2012</xref>). Taken together, these factors led us to hypothesise that the inactivation of fumarase and the adaptive response could also help to make bacteria more susceptible to antibiotics.</p><p>Here, we first screened the impact of multiple antimicrobial agents on inactivated strains of <italic>E. coli</italic> BW25113 &#x00394;<italic>fumA</italic>, &#x00394;<italic>fumB</italic>, &#x00394;<italic>fumC</italic> (fumarases) and &#x00394;<italic>alkA</italic>, &#x00394;<italic>alkB</italic> and &#x00394;<italic>aidB</italic> (adaptive response) (<xref rid="fig1" ref-type="fig">Figure 1</xref>, <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S1</xref>). These inactivations had no or very little effect on antibiotic susceptibility. Similar results have previously been described in <italic>E. coli</italic> CFT073 &#x00394;<italic>fumA</italic>, &#x00394;<italic>fumB</italic>, &#x00394;<italic>fumC</italic> mutants for chloramphenicol, trimethoprim, tetracycline, ciprofloxacin, ampicillin and streptomycin, although the latter demonstrated an elevated MIC for &#x00394;<italic>fumC</italic> (<xref rid="ref22" ref-type="bibr">Himpsl et al., 2020</xref>). It is also noteworthy that <italic>fumC</italic> deficiency in <italic>Staphylococcus aureus</italic> results in higher tolerance to ciprofloxacin, gentamycin and oxacillin due to reduced ATP intracellular levels (<xref rid="ref50" ref-type="bibr">Zalis et al., 2019</xref>). Of the inactivations targeted in our study, those of <italic>fumC</italic> and <italic>aidB</italic> had the greatest effect, particularly against penicillins and cephalosporins. FumC is a class II fumarase, that is, a fumarase without a catalytic Fe-S cluster, as opposed to the class I fumarases FumA and FumB, which do contain this cluster (<xref rid="ref48" ref-type="bibr">Woods et al., 1988</xref>; <xref rid="ref44" ref-type="bibr">Ueda et al., 1991</xref>). Fe-S clusters are typically oxidised in the presence of ROS (<xref rid="ref18" ref-type="bibr">Flint et al., 1993</xref>). Consequently, in the presence of antibiotics that induce oxidative stress, FumA and FumB may lose their catalytic activity, leaving only FumC as the active fumarase. Previous studies have shown that in the absence of FumA and FumB, FumC participates in the response to DNA damage and TCA cycle functions (<xref rid="ref39" ref-type="bibr">Silas et al., 2021</xref>). In the context of a &#x00394;<italic>fumC</italic> mutant, the absence of FumA and FumB would mean the lack of fumarase activity during antibiotic-induced oxidative stress. This could be one explanation for the increased susceptibility observed in &#x00394;<italic>fumC</italic> compared to the other mutants. In addition, inactivation of fumarases in the TCA cycle may also trigger metabolic perturbations that also affect antibiotic susceptibility. For example, fumarase deficiency in <italic>Mycobacterium tuberculosis</italic> is bactericidal due to an accumulation of fumarate, which intereferes with catalase and mycothiol antioxidants, ultimately leading to oxidative stress (<xref rid="ref37" ref-type="bibr">Ruecker et al., 2017</xref>). In this sense, fumarase inhibitors have been developed for this bacterium in the search for novel antibacterial compounds (<xref rid="ref47" ref-type="bibr">Whitehouse et al., 2019</xref>).</p><p>Regarding the adaptive response, it is already known that inactivating <italic>alkA</italic> and <italic>alkB</italic> leads to increased susceptibility to kanamycin, while <italic>alkB</italic> inactivation does not affect survival to ciprofloxacin (<xref rid="ref24" ref-type="bibr">Kang et al., 2012</xref>). In our screening with multiple antimicrobial agents, we only detected small or negligible increments in the susceptibility of &#x00394;<italic>alkA</italic>, &#x00394;<italic>alkB</italic> and &#x00394;<italic>aidB</italic>. AidB is a component of the adaptive response, and its function is as yet unclear. It shows homology to acyl-CoA oxidases and has been reported to bind to double-strand DNA for dealkylation (<xref rid="ref32" ref-type="bibr">Mielecki and Grzesiuk, 2014</xref>). Of note, inactivation of <italic>aidB</italic> in <italic>E. coli</italic> does not appear to affect bacterial survival in the presence of MMS (<xref rid="ref35" ref-type="bibr">Rippa et al., 2011</xref>). Previous studies have shown that Ada, the transcriptional regulator of the adaptive response, is induced in the presence of MMS and subinhibitory concentrations of aminoglycosides, <italic>&#x003b2;</italic>-lactams and quinolones (<xref rid="ref19" ref-type="bibr">Gutierrez et al., 2013</xref>), suggesting that this mechanism may be involved in the antibiotic-induced stress response. Indeed, <italic>ada</italic> is regulated by the general RpoS stress response regulon, which enables bacteria to combat antibiotic stress induced by metabolic disturbances and ROS production (<xref rid="ref46" ref-type="bibr">Weber et al., 2005</xref>; <xref rid="ref6" ref-type="bibr">Bl&#x000e1;zquez et al., 2018</xref>). This may explain why we observed some increases in antibiotic susceptibility in the absence of adaptive response genes.</p><p>Given the modest differences obtained, we decided to inactivate fumarases and the adaptive response together with the SOS response. Targeting the SOS response through <italic>recA</italic> inactivation has been shown to reverse quinolone resistance <italic>in vitro</italic> and <italic>in vivo</italic> (<xref rid="ref34" ref-type="bibr">Recacha et al., 2017</xref>; <xref rid="ref29" ref-type="bibr">Machuca et al., 2021</xref>). Furthermore, the combined inactivation of <italic>recA</italic> and other anti-genotoxic stress pathways, such as the ROS detoxification systems (<italic>sodB, katG</italic>) or Dam methylase, resulted in an enhanced or even synergistic increase in susceptibility (<xref rid="ref14" ref-type="bibr">Diaz-Diaz et al., 2021</xref>, <xref rid="ref15" ref-type="bibr">2023</xref>). In this study, attending to the disc difussion results (<xref rid="fig2" ref-type="fig">Figure 2</xref>, <xref rid="SM1" ref-type="supplementary-material">Supplementary Figures S2, S3</xref>), we observed that strains doubly defective for <italic>fumC</italic>/<italic>recA</italic> or <italic>aidB</italic>/<italic>recA</italic> tended to be increasingly susceptible to various antimicrobial agents (<xref rid="fig2" ref-type="fig">Figure 2</xref>, <xref rid="SM1" ref-type="supplementary-material">Supplementary Figures S2, S3</xref>). This effect was particularly marked for &#x003b2;-lactams and was not found after inactivation of &#x00394;<italic>recA</italic> alone. In the presence of a quinolone (ciprofloxacin) and a &#x003b2;-lactam (cefepime), the double mutants showed delayed or no growth. In terms of survival and the ability to evolve resistance, cefepime activity was potentiated by double inactivations, particularly &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic>. These results are consistent with the reduced survival of a &#x00394;<italic>lexA3</italic>/&#x00394;<italic>ada</italic> mutant following continuous exposure to MMS (<xref rid="ref45" ref-type="bibr">Uphoff, 2018</xref>). However, in the presence of ciprofloxacin, double inactivations had no effect on survival or capacity to evolve compared to &#x00394;<italic>recA.</italic> This can also be seen as a positive outcome, as in previous studies carried out in our laboratory, targeting the SOS response together with ROS detoxification systems improved evolvability compared to single &#x00394;<italic>recA</italic> inactivation (<xref rid="ref13" ref-type="bibr">Diaz-Diaz et al., 2022</xref>).</p><p>It is likely that the lack of two distinct DNA damage responses makes it more difficult for bacteria to overcome the side effects of antibiotic-induced stress. Although the SOS response and the adaptive response act on gene damage, the outcome of their activity is very different. The adaptive response involves the faithful repair of alkylation damage, whereas the SOS response activates low-fidelity polymerases that increase the rate of mutagenesis and thus the likelihood of resistance emergence beyond DNA repair. Similarly, the SOS response to MMS is activated more rapidly than the adaptive response, so that the inactivation of both pathways would prevent DNA repair for a longer period of time (<xref rid="ref45" ref-type="bibr">Uphoff, 2018</xref>; <xref rid="ref23" ref-type="bibr">Kamat and Badrinarayanan, 2023</xref>). It is also worth mentioning that the activity of the SOS response in <italic>Bacillus subtilis</italic> depends partly on the activity of the fumarase Fum-bc, which is recruited to DNA double-strand breaks produced by MMS. Through the production of L-malate, Fum-bc upregulates the local translation of RecN, one of the first proteins recruited to DNA damage sites during the SOS response to promote repair (<xref rid="ref1" ref-type="bibr">Alonso et al., 2013</xref>; <xref rid="ref40" ref-type="bibr">Singer et al., 2017</xref>; <xref rid="ref26" ref-type="bibr">Leshets et al., 2018</xref>). The absence of Fum-bc would also presumably delay RecN-dependent repair. In other words, all these pathways are also interconnected, which explains why targeting them together has a greater effect on sensitisation.</p><p>Since the inactivation of fumarases, the adaptive response and the SOS response enhanced antimicrobial activity in a susceptible <italic>E. coli</italic> strain, we assessed these results in a strain with intrinsic resistance mechanisms. The FI20 clinical isolate was selected to reproduce these experiments (<xref rid="fig3" ref-type="fig">Figure 3</xref>, <xref rid="SM1" ref-type="supplementary-material">Supplementary Figures S4, S5</xref>). This strain belongs to the high-risk ST131 clone and contains mutations in <italic>gyrB</italic> and <italic>parC</italic> that confer quinolone resistance (<xref rid="ref21" ref-type="bibr">Hernandez et al., 2011</xref>; <xref rid="ref29" ref-type="bibr">Machuca et al., 2021</xref>). Since the BW25113 &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> mutant showed slightly higher differences on susceptibility for various antimicrobial agents than BW25113 &#x00394;<italic>aidB</italic>/&#x00394;<italic>recA</italic>, it was decided to focus on the first strategy and to generate a FI20 &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> mutant. As with the BW25113 strain, single inactivation of &#x00394;<italic>fumC</italic> resulted in very modest differences in susceptibility, in this case, to miscellaneous agents. Interestingly, &#x00394;<italic>fumC</italic> deficiency in FI20 also had a negative effect on growth under antibiotic exposure, in contrast to the susceptible BW25113 strain. With respect to the FI20 &#x00394;<italic>fumC</italic>/&#x00394;<italic>recA</italic> mutant, we again observed a marked increase in susceptibility, which was significant mainly for quinolones and miscellaneous agents such as rifampicin. This suggests that in addition to the higher sensitisation achieved by <italic>recA</italic> inactivation in BW25113, this strategy further enhances quinolone efficacy in a resistant strain. This is consistent with the results obtained from growth curves and spot tests.</p><p>In general, the results of this study indicate that the differences between the various techniques used were not always equitable and that the gene inactivations evaluated did not consistently result in high fold-reductions in MIC values. Nevertheless, we showed that there were significant changes in antibiotic susceptibility at the biological level and using different approaches. It is important to highlight that the correlation between MIC and pharmacodynamic parameters is not always exact (<xref rid="ref36" ref-type="bibr">Rodr&#x000ed;guez-Mart&#x000ed;nez et al., 2016</xref>). In the case of the FI20 clinical isolate, growth curves and spot tests showed that, when fumarase and the <italic>recA</italic>-dependent SOS response were absent, moderate concentrations of antibiotic had a marked effect on the susceptibility of this LLQR bacterium, suggesting that this strategy may have potential clinical applicability in the treatment of this resistant phenotype.</p><p>Overall, the present study shows that combined inactivation of fumarase and the SOS response is a potential sensitisation strategy that has not been previously considered or characterised. It also shows that this phenomenon applies to antimicrobials and not only to alkylating agents, and suggests ways for new therapeutic strategies to combat antimicrobial resistance and enhance antibiotic activity.</p></sec></body><back><sec sec-type="data-availability" id="sec19"><title>Data availability statement</title><p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/</ext-link>, PRJNA1015411.</p></sec><sec sec-type="author-contributions" id="sec20"><title>Author contributions</title><p>MM-T: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing, Visualization. IP-F: Data curation, Formal analysis, Investigation, Methodology, Validation, Writing &#x02013; review &#x00026; editing. MQ-D: Data curation, Formal analysis, Investigation, Methodology, Validation, Writing &#x02013; review &#x00026; editing. SD-D: Conceptualization, Investigation, Methodology, Validation, Writing &#x02013; review &#x00026; editing. MR-M: Investigation, Methodology, Validation, Writing &#x02013; review &#x00026; editing. ER: Funding acquisition, Writing &#x02013; review &#x00026; editing. FD-P: Conceptualization, Writing &#x02013; review &#x00026; editing. JR-M: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="sec22"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p></sec><sec sec-type="ai-statement" id="sec23"><title>Generative AI statement</title><p>The authors declare that no Gen AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="sec24"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="sec25"><title>Supplementary material</title><p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fmicb.2025.1570764/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fmicb.2025.1570764/full#supplementary-material</ext-link></p><supplementary-material id="SM1" position="float" content-type="local-data"><media xlink:href="Data_sheet_1.DOCX"/></supplementary-material></sec><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alonso</surname><given-names>J. C.</given-names></name><name><surname>Cardenas</surname><given-names>P. P.</given-names></name><name><surname>Sanchez</surname><given-names>H.</given-names></name><name><surname>Hejna</surname><given-names>J.</given-names></name><name><surname>Suzuki</surname><given-names>Y.</given-names></name><name><surname>Takeyasu</surname><given-names>K.</given-names></name></person-group> (<year>2013</year>). <article-title>Early steps of double-strand break repair in <italic>Bacillus subtilis</italic></article-title>. <source>DNA Repair</source>
<volume>12</volume>, <fpage>162</fpage>&#x02013;<lpage>176</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.dnarep.2012.12.005</pub-id>, PMID: <pub-id pub-id-type="pmid">23380520</pub-id>
</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baba</surname><given-names>T.</given-names></name><name><surname>Ara</surname><given-names>T.</given-names></name><name><surname>Hasegawa</surname><given-names>M.</given-names></name><name><surname>Takai</surname><given-names>Y.</given-names></name><name><surname>Okumura</surname><given-names>Y.</given-names></name><name><surname>Baba</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2006</year>). <article-title>Construction of <italic>Escherichia coli</italic> K-12 in-frame, single-gene knockout mutants: the Keio collection</article-title>. <source>Mol. Syst. Biol.</source>
<volume>2</volume>:<fpage>0008</fpage>. doi: <pub-id pub-id-type="doi">10.1038/msb4100050</pub-id>, PMID: <pub-id pub-id-type="pmid">16738554</pub-id>
</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>S. J.</given-names></name><name><surname>Payne</surname><given-names>D. J.</given-names></name><name><surname>Rappuoli</surname><given-names>R.</given-names></name><name><surname>De Gregorio</surname><given-names>E.</given-names></name></person-group> (<year>2018</year>). <article-title>Technologies to address antimicrobial resistance</article-title>. <source>Proc. Natl. Acad. Sci. USA</source>
<volume>115</volume>, <fpage>12887</fpage>&#x02013;<lpage>12895</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1717160115</pub-id>, PMID: <pub-id pub-id-type="pmid">30559181</pub-id>
</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belenky</surname><given-names>P.</given-names></name><name><surname>Ye</surname><given-names>J. D.</given-names></name><name><surname>Porter</surname><given-names>C. B. M.</given-names></name><name><surname>Cohen</surname><given-names>N. R.</given-names></name><name><surname>Lobritz</surname><given-names>M. A.</given-names></name><name><surname>Ferrante</surname><given-names>T.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Bactericidal antibiotics induce toxic metabolic perturbations that lead to cellular damage</article-title>. <source>Cell Rep.</source>
<volume>13</volume>, <fpage>968</fpage>&#x02013;<lpage>980</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2015.09.059</pub-id>, PMID: <pub-id pub-id-type="pmid">26565910</pub-id>
</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bl&#x000e1;zquez</surname><given-names>J.</given-names></name><name><surname>Couce</surname><given-names>A.</given-names></name><name><surname>Rodr&#x000ed;guez-Beltr&#x000e1;n</surname><given-names>J.</given-names></name><name><surname>Rodr&#x000ed;guez-Rojas</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>Antimicrobials as promoters of genetic variation</article-title>. <source>Curr. Opin. Microbiol.</source>
<volume>15</volume>, <fpage>561</fpage>&#x02013;<lpage>569</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mib.2012.07.007</pub-id>, PMID: <pub-id pub-id-type="pmid">22890188</pub-id>
</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bl&#x000e1;zquez</surname><given-names>J.</given-names></name><name><surname>Rodr&#x000ed;guez-Beltr&#x000e1;n</surname><given-names>J.</given-names></name><name><surname>Matic</surname><given-names>I.</given-names></name></person-group> (<year>2018</year>). <article-title>Antibiotic-induced genetic variation: how it arises and how it can be prevented</article-title>. <source>Ann. Rev. Microbiol.</source>
<volume>72</volume>, <fpage>209</fpage>&#x02013;<lpage>230</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev-micro-090817-062139</pub-id><pub-id pub-id-type="pmid">30200850</pub-id>
</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaveroche</surname><given-names>M.-K.</given-names></name><name><surname>Ghigo</surname><given-names>J.-M.</given-names></name><name><surname>d&#x02019;Enfert</surname><given-names>C.</given-names></name></person-group> (<year>2000</year>). <article-title>A rapid method for efficient gene replacement in the filamentous fungus <italic>aspergillus nidulans</italic></article-title>. <source>Nucleic Acids Res.</source>
<volume>28</volume>:<fpage>e97</fpage>, <fpage>97e</fpage>&#x02013;<lpage>997e</lpage>. doi: <pub-id pub-id-type="doi">10.1093/nar/28.22.e97</pub-id>, PMID: <pub-id pub-id-type="pmid">11071951</pub-id>
</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="book"><person-group person-group-type="author"><collab id="coll1">CLSI</collab></person-group> (<year>n.d.</year>). <source>Performance standards for antimicrobial susceptibility testing</source>. <edition>34th</edition> Edn: <publisher-name>CLSI Guideline M100</publisher-name>. Available at: <ext-link xlink:href="https://clsi.org/shop/standards/m100/" ext-link-type="uri">https://clsi.org/shop/standards/m100/</ext-link></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>M. A.</given-names></name><name><surname>Wright</surname><given-names>G. D.</given-names></name></person-group> (<year>2022</year>). <article-title>The past, present, and future of antibiotics</article-title>. <source>Sci. Transl. Med.</source>
<volume>14</volume>:<fpage>eabo7793</fpage>. doi: <pub-id pub-id-type="doi">10.1126/scitranslmed.abo7793</pub-id>, PMID: <pub-id pub-id-type="pmid">35947678</pub-id>
</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crane</surname><given-names>J. K.</given-names></name><name><surname>Alvarado</surname><given-names>C. L.</given-names></name><name><surname>Sutton</surname><given-names>M. D.</given-names></name></person-group> (<year>2021</year>). <article-title>Role of the SOS response in the generation of antibiotic resistance <italic>in vivo</italic></article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>65</volume>:<fpage>e0001321</fpage>. doi: <pub-id pub-id-type="doi">10.1128/aac.00013-21</pub-id>, PMID: <pub-id pub-id-type="pmid">33875437</pub-id>
</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datsenko</surname><given-names>K. A.</given-names></name><name><surname>Wanner</surname><given-names>B. L.</given-names></name></person-group> (<year>2000</year>). <article-title>One-step inactivation of chromosomal genes in <italic>Escherichia coli</italic> K-12 using PCR products</article-title>. <source>Proc. Natl. Acad. Sci.</source>
<volume>97</volume>, <fpage>6640</fpage>&#x02013;<lpage>6645</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.120163297</pub-id>, PMID: <pub-id pub-id-type="pmid">10829079</pub-id>
</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawan</surname><given-names>J.</given-names></name><name><surname>Ahn</surname><given-names>J.</given-names></name></person-group> (<year>2022</year>). <article-title>Bacterial stress responses as potential targets in overcoming antibiotic resistance</article-title>. <source>Microorganisms</source>
<volume>10</volume>:<fpage>1385</fpage>. doi: <pub-id pub-id-type="doi">10.3390/microorganisms10071385</pub-id>, PMID: <pub-id pub-id-type="pmid">35889104</pub-id>
</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Diaz</surname><given-names>S.</given-names></name><name><surname>Recacha</surname><given-names>E.</given-names></name><name><surname>Garc&#x000ed;a-Duque</surname><given-names>A.</given-names></name><name><surname>Docobo-P&#x000e9;rez</surname><given-names>F.</given-names></name><name><surname>Bl&#x000e1;zquez</surname><given-names>J.</given-names></name><name><surname>Pascual</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2022</year>). <article-title>Effect of RecA inactivation and detoxification systems on the evolution of ciprofloxacin resistance in <italic>Escherichia coli</italic></article-title>. <source>J. Antimicrob. Chemother.</source>
<volume>77</volume>, <fpage>641</fpage>&#x02013;<lpage>645</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/dkab445</pub-id>, PMID: <pub-id pub-id-type="pmid">34878138</pub-id>
</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Diaz</surname><given-names>S.</given-names></name><name><surname>Recacha</surname><given-names>E.</given-names></name><name><surname>Machuca</surname><given-names>J.</given-names></name><name><surname>Garc&#x000ed;a-Duque</surname><given-names>A.</given-names></name><name><surname>Docobo-P&#x000e9;rez</surname><given-names>F.</given-names></name><name><surname>Bl&#x000e1;zquez</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Synergistic quinolone sensitization by targeting the <italic>recA</italic> SOS response gene and oxidative stress</article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>65</volume>:<fpage>e02004-20</fpage>. doi: <pub-id pub-id-type="doi">10.1128/aac.02004-20</pub-id>, PMID: <pub-id pub-id-type="pmid">33526493</pub-id>
</mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Diaz</surname><given-names>S.</given-names></name><name><surname>Recacha</surname><given-names>E.</given-names></name><name><surname>Pulido</surname><given-names>M. R.</given-names></name><name><surname>Romero-Mu&#x000f1;oz</surname><given-names>M.</given-names></name><name><surname>De Gregorio-Iaria</surname><given-names>B.</given-names></name><name><surname>Docobo-P&#x000e9;rez</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2023</year>). <article-title>Synergistic effect of SOS response and GATC methylome suppression on antibiotic stress survival in <italic>Escherichia coli</italic></article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>67</volume>:<fpage>e0139222</fpage>. doi: <pub-id pub-id-type="doi">10.1128/aac.01392-22</pub-id>, PMID: <pub-id pub-id-type="pmid">36802234</pub-id>
</mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drlica</surname><given-names>K.</given-names></name></person-group> (<year>1999</year>). <article-title>Mechanism of fluoroquinolone action</article-title>. <source>Curr. Opin. Microbiol.</source>
<volume>2</volume>, <fpage>504</fpage>&#x02013;<lpage>508</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1369-5274(99)00008-9</pub-id>, PMID: <pub-id pub-id-type="pmid">10508721</pub-id>
</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudero</surname><given-names>J. A.</given-names></name><name><surname>MacLean</surname><given-names>R. C.</given-names></name><name><surname>San</surname><given-names>M. A.</given-names></name></person-group> (<year>2018</year>). <article-title>Testing the role of multicopy plasmids in the evolution of antibiotic resistance</article-title>. <source>J. Vis. Exp.</source>
<volume>2018</volume>:<fpage>57386</fpage>. doi: <pub-id pub-id-type="doi">10.3791/57386</pub-id>, PMID: <pub-id pub-id-type="pmid">29781985</pub-id>
</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flint</surname><given-names>D. H.</given-names></name><name><surname>Tuminello</surname><given-names>J. F.</given-names></name><name><surname>Emptage</surname><given-names>M. H.</given-names></name></person-group> (<year>1993</year>). <article-title>The inactivation of Fe-S cluster containing hydro-lyases by superoxide</article-title>. <source>J. Biol. Chem.</source>
<volume>268</volume>, <fpage>22369</fpage>&#x02013;<lpage>22376</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0021-9258(18)41538-4</pub-id>, PMID: <pub-id pub-id-type="pmid">8226748</pub-id>
</mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutierrez</surname><given-names>A.</given-names></name><name><surname>Laureti</surname><given-names>L.</given-names></name><name><surname>Crussard</surname><given-names>S.</given-names></name><name><surname>Abida</surname><given-names>H.</given-names></name><name><surname>Rodr&#x000ed;guez-Rojas</surname><given-names>A.</given-names></name><name><surname>Bl&#x000e1;zquez</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>&#x003b2;-Lactam antibiotics promote bacterial mutagenesis via an RpoS-mediated reduction in replication fidelity</article-title>. <source>Nat. Commun.</source>
<volume>4</volume>:<fpage>1610</fpage>. doi: <pub-id pub-id-type="doi">10.1038/ncomms2607</pub-id>, PMID: <pub-id pub-id-type="pmid">23511474</pub-id>
</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halawa</surname><given-names>E. M.</given-names></name><name><surname>Fadel</surname><given-names>M.</given-names></name><name><surname>Al-Rabia</surname><given-names>M. W.</given-names></name><name><surname>Behairy</surname><given-names>A.</given-names></name><name><surname>Nouh</surname><given-names>N. A.</given-names></name><name><surname>Abdo</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2024</year>). <article-title>Antibiotic action and resistance: updated review of mechanisms, spread, influencing factors, and alternative approaches for combating resistance</article-title>. <source>Front. Pharmacol.</source>
<volume>14</volume>:<fpage>1305294</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2023.1305294</pub-id>, PMID: <pub-id pub-id-type="pmid">38283841</pub-id>
</mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>A.</given-names></name><name><surname>Sanchez</surname><given-names>M. B.</given-names></name><name><surname>Martinez</surname><given-names>J. L.</given-names></name></person-group> (<year>2011</year>). <article-title>Quinolone resistance: much more than predicted</article-title>. <source>Front. Microbiol.</source>
<volume>2</volume>:<fpage>22</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2011.00022</pub-id>, PMID: <pub-id pub-id-type="pmid">21687414</pub-id>
</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Himpsl</surname><given-names>S. D.</given-names></name><name><surname>Shea</surname><given-names>A. E.</given-names></name><name><surname>Zora</surname><given-names>J.</given-names></name><name><surname>Stocki</surname><given-names>J. A.</given-names></name><name><surname>Foreman</surname><given-names>D.</given-names></name><name><surname>Alteri</surname><given-names>C. J.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>The oxidative fumarase FumC is a key contributor for <italic>E. coli</italic> fitness under iron-limitation and during UTI</article-title>. <source>PLoS Pathog.</source>
<volume>16</volume>:<fpage>e1008382</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1008382</pub-id>, PMID: <pub-id pub-id-type="pmid">32106241</pub-id>
</mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamat</surname><given-names>A.</given-names></name><name><surname>Badrinarayanan</surname><given-names>A.</given-names></name></person-group> (<year>2023</year>). <article-title>SOS-independent bacterial DNA damage responses: diverse mechanisms, unifying function</article-title>. <source>Curr. Opin. Microbiol.</source>
<volume>73</volume>:<fpage>102323</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mib.2023.102323</pub-id>, PMID: <pub-id pub-id-type="pmid">37148591</pub-id>
</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>T. M.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Nguyen</surname><given-names>A.</given-names></name><name><surname>Becket</surname><given-names>E.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Miller</surname><given-names>J. H.</given-names></name></person-group> (<year>2012</year>). <article-title>The aminoglycoside antibiotic kanamycin damages DNA bases in <italic>Escherichia coli</italic>: caffeine potentiates the DNA-damaging effects of kanamycin while suppressing cell killing by ciprofloxacin in <italic>Escherichia coli</italic> and <italic>Bacillus anthracis</italic></article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>56</volume>, <fpage>3216</fpage>&#x02013;<lpage>3223</lpage>. doi: <pub-id pub-id-type="doi">10.1128/aac.00066-12</pub-id>, PMID: <pub-id pub-id-type="pmid">22391551</pub-id>
</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ledger</surname><given-names>E. V. K.</given-names></name><name><surname>Lau</surname><given-names>K.</given-names></name><name><surname>Tate</surname><given-names>E. W.</given-names></name><name><surname>Edwards</surname><given-names>A. M.</given-names></name></person-group> (<year>2023</year>). <article-title>XerC is required for the repair of antibiotic- and immune-mediated DNA damage in <italic>Staphylococcus aureus</italic></article-title>. <source>Antimicrob. Agents Chemother.</source>
<volume>67</volume>:<fpage>e0120622</fpage>. doi: <pub-id pub-id-type="doi">10.1128/aac.01206-22</pub-id>, PMID: <pub-id pub-id-type="pmid">36802166</pub-id>
</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leshets</surname><given-names>M.</given-names></name><name><surname>Silas</surname><given-names>Y. B. H.</given-names></name><name><surname>Lehming</surname><given-names>N.</given-names></name><name><surname>Pines</surname><given-names>O.</given-names></name></person-group> (<year>2018</year>). <article-title>Fumarase: from the TCA cycle to DNA damage response and tumor suppression</article-title>. <source>Front. Mol. Biosci.</source>
<volume>5</volume>:<fpage>68</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmolb.2018.00068</pub-id>, PMID: <pub-id pub-id-type="pmid">30090811</pub-id>
</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Xiao</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name></person-group> (<year>2019</year>). <article-title>Bacterial metabolism-inspired molecules to modulate antibiotic efficacy</article-title>. <source>J. Antimicrob. Chemother.</source>
<volume>74</volume>, <fpage>3409</fpage>&#x02013;<lpage>3417</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/dkz230</pub-id>, PMID: <pub-id pub-id-type="pmid">31211378</pub-id>
</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez-Cerero</surname><given-names>L.</given-names></name><name><surname>Bellido</surname><given-names>M. D. M.</given-names></name><name><surname>Serrano</surname><given-names>L.</given-names></name><name><surname>Lir&#x000f3;</surname><given-names>J.</given-names></name><name><surname>Cisneros</surname><given-names>J. M.</given-names></name><name><surname>Rodr&#x000ed;guez-Ba&#x000f1;o</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title><italic>Escherichia coli</italic> O25b:H4/ST131 are prevalent in Spain and are often not associated with ESBL or quinolone resistance</article-title>. <source>Enferm. Infecc. Microbiol. Clin.</source>
<volume>31</volume>, <fpage>385</fpage>&#x02013;<lpage>388</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.eimc.2012.09.005</pub-id>, PMID: <pub-id pub-id-type="pmid">23182241</pub-id>
</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machuca</surname><given-names>J.</given-names></name><name><surname>Recacha</surname><given-names>E.</given-names></name><name><surname>Gallego-Mesa</surname><given-names>B.</given-names></name><name><surname>Diaz-Diaz</surname><given-names>S.</given-names></name><name><surname>Rojas-Granado</surname><given-names>G.</given-names></name><name><surname>Garcia-Duque</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2021</year>). <article-title>Effect of RecA inactivation on quinolone susceptibility and the evolution of resistance in clinical isolates of <italic>Escherichia coli</italic></article-title>. <source>J. Antimicrob. Chemother.</source>
<volume>76</volume>, <fpage>338</fpage>&#x02013;<lpage>344</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/dkaa448</pub-id>, PMID: <pub-id pub-id-type="pmid">33147333</pub-id>
</mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maslowska</surname><given-names>K. H.</given-names></name><name><surname>Makiela-Dzbenska</surname><given-names>K.</given-names></name><name><surname>Fijalkowska</surname><given-names>I. J.</given-names></name></person-group> (<year>2019</year>). <article-title>The SOS system: a complex and tightly regulated response to DNA damage</article-title>. <source>Environ. Mol. Mutagen.</source>
<volume>60</volume>, <fpage>368</fpage>&#x02013;<lpage>384</lpage>. doi: <pub-id pub-id-type="doi">10.1002/em.22267</pub-id>, PMID: <pub-id pub-id-type="pmid">30447030</pub-id>
</mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Memar</surname><given-names>M. Y.</given-names></name><name><surname>Yekani</surname><given-names>M.</given-names></name><name><surname>Celenza</surname><given-names>G.</given-names></name><name><surname>Poortahmasebi</surname><given-names>V.</given-names></name><name><surname>Naghili</surname><given-names>B.</given-names></name><name><surname>Bellio</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2020</year>). <article-title>The central role of the SOS DNA repair system in antibiotics resistance: a new target for a new infectious treatment strategy</article-title>. <source>Life Sci.</source>
<volume>262</volume>:<fpage>118562</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.lfs.2020.118562</pub-id>, PMID: <pub-id pub-id-type="pmid">33038378</pub-id>
</mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mielecki</surname><given-names>D.</given-names></name><name><surname>Grzesiuk</surname><given-names>E.</given-names></name></person-group> (<year>2014</year>). <article-title>Ada response - a strategy for repair of alkylated DNA in bacteria</article-title>. <source>FEMS Microbiol. Lett.</source>
<volume>355</volume>, <fpage>1</fpage>&#x02013;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1111/1574-6968.12462</pub-id>, PMID: <pub-id pub-id-type="pmid">24810496</pub-id>
</mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mielecki</surname><given-names>D.</given-names></name><name><surname>Wrzesi&#x00144;ski</surname><given-names>M.</given-names></name><name><surname>Grzesiuk</surname><given-names>E.</given-names></name></person-group> (<year>2015</year>). <article-title>Inducible repair of alkylated DNA in microorganisms</article-title>. <source>Mutat. Res. Rev. Mutat. Res.</source>
<volume>763</volume>, <fpage>294</fpage>&#x02013;<lpage>305</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mrrev.2014.12.001</pub-id>, PMID: <pub-id pub-id-type="pmid">25795127</pub-id>
</mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Recacha</surname><given-names>E.</given-names></name><name><surname>Machuca</surname><given-names>J.</given-names></name><name><surname>D&#x000ed;az De Alba</surname><given-names>P.</given-names></name><name><surname>Ramos-G&#x000fc;elfo</surname><given-names>M.</given-names></name><name><surname>Docobo-P&#x000e9;rez</surname><given-names>F.</given-names></name><name><surname>Rodriguez-Beltr&#x000e1;n</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Quinolone resistance reversion by targeting the SOS response</article-title>. <source>MBio</source>
<volume>8</volume>:<fpage>e00971-17</fpage>. doi: <pub-id pub-id-type="doi">10.1128/mbio.00971-17</pub-id><pub-id pub-id-type="pmid">29018116</pub-id>
</mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rippa</surname><given-names>V.</given-names></name><name><surname>Duilio</surname><given-names>A.</given-names></name><name><surname>di Pasquale</surname><given-names>P.</given-names></name><name><surname>Amoresano</surname><given-names>A.</given-names></name><name><surname>Landini</surname><given-names>P.</given-names></name><name><surname>Volkert</surname><given-names>M. R.</given-names></name></person-group> (<year>2011</year>). <article-title>Preferential DNA damage prevention by the <italic>E. coli AidB</italic> gene: a new mechanism for the protection of specific genes</article-title>. <source>DNA Repair</source>
<volume>10</volume>, <fpage>934</fpage>&#x02013;<lpage>941</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.dnarep.2011.06.001</pub-id>, PMID: <pub-id pub-id-type="pmid">21788159</pub-id>
</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez-Mart&#x000ed;nez</surname><given-names>J. M.</given-names></name><name><surname>Machuca</surname><given-names>J.</given-names></name><name><surname>Cano</surname><given-names>M. E.</given-names></name><name><surname>Calvo</surname><given-names>J.</given-names></name><name><surname>Mart&#x000ed;nez-Mart&#x000ed;nez</surname><given-names>L.</given-names></name><name><surname>Pascual</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Plasmid-mediated quinolone resistance: two decades on</article-title>. <source>Drug Resist. Updat.</source>
<volume>29</volume>, <fpage>13</fpage>&#x02013;<lpage>29</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.drup.2016.09.001</pub-id>, PMID: <pub-id pub-id-type="pmid">27912841</pub-id>
</mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruecker</surname><given-names>N.</given-names></name><name><surname>Jansen</surname><given-names>R.</given-names></name><name><surname>Trujillo</surname><given-names>C.</given-names></name><name><surname>Puckett</surname><given-names>S.</given-names></name><name><surname>Jayachandran</surname><given-names>P.</given-names></name><name><surname>Piroli</surname><given-names>G. G.</given-names></name><etal/></person-group>. (<year>2017</year>). <article-title>Fumarase deficiency causes protein and metabolite succination and intoxicates <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Cell Chem. Biol.</source>
<volume>24</volume>, <fpage>306</fpage>&#x02013;<lpage>315</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.chembiol.2017.01.005</pub-id>, PMID: <pub-id pub-id-type="pmid">28219662</pub-id>
</mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>R. S.</given-names></name></person-group> (<year>2015</year>). <article-title>Antimicrobial-induced DNA damage and genomic instability in microbial pathogens</article-title>. <source>PLoS Pathog.</source>
<volume>11</volume>:<fpage>e1004678</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.ppat.1004678</pub-id>, PMID: <pub-id pub-id-type="pmid">25811381</pub-id>
</mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silas</surname><given-names>Y.</given-names></name><name><surname>Singer</surname><given-names>E.</given-names></name><name><surname>Das</surname><given-names>K.</given-names></name><name><surname>Lehming</surname><given-names>N.</given-names></name><name><surname>Pines</surname><given-names>O.</given-names></name></person-group> (<year>2021</year>). <article-title>A combination of class-I fumarases and metabolites (&#x003b1;-ketoglutarate and fumarate) signal the DNA damage response in <italic>Escherichia coli</italic></article-title>. <source>Proc. Natl. Acad. Sci. USA</source>
<volume>118</volume>:<fpage>e2026595118</fpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.2026595118</pub-id>, PMID: <pub-id pub-id-type="pmid">34083440</pub-id>
</mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>E.</given-names></name><name><surname>Silas</surname><given-names>Y. B.</given-names></name><name><surname>Ben-Yehuda</surname><given-names>S.</given-names></name><name><surname>Pines</surname><given-names>O.</given-names></name></person-group> (<year>2017</year>). <article-title>Bacterial fumarase and L-malic acid are evolutionary ancient components of the DNA damage response</article-title>. <source>eLife</source>
<volume>6</volume>:<fpage>e30927</fpage>. doi: <pub-id pub-id-type="doi">10.7554/eLife.30927</pub-id>, PMID: <pub-id pub-id-type="pmid">29140245</pub-id>
</mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sprouffske</surname><given-names>K.</given-names></name><name><surname>Wagner</surname><given-names>A.</given-names></name></person-group> (<year>2016</year>). <article-title>Growthcurver: an R package for obtaining interpretable metrics from microbial growth curves</article-title>. <source>BMC Bioinformatics</source>
<volume>17</volume>:<fpage>172</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12859-016-1016-7</pub-id>, PMID: <pub-id pub-id-type="pmid">27094401</pub-id>
</mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stokes</surname><given-names>J. M.</given-names></name><name><surname>Lopatkin</surname><given-names>A. J.</given-names></name><name><surname>Lobritz</surname><given-names>M. A.</given-names></name><name><surname>Collins</surname><given-names>J. J.</given-names></name></person-group> (<year>2019</year>). <article-title>Bacterial metabolism and antibiotic efficacy</article-title>. <source>Cell Metab.</source>
<volume>30</volume>, <fpage>251</fpage>&#x02013;<lpage>259</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmet.2019.06.009</pub-id>, PMID: <pub-id pub-id-type="pmid">31279676</pub-id>
</mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomason</surname><given-names>L. C.</given-names></name><name><surname>Costantino</surname><given-names>N.</given-names></name><name><surname>Court</surname><given-names>D. L.</given-names></name></person-group> (<year>2007</year>). <article-title><italic>E. coli</italic> genome manipulation by P1 transduction</article-title>. <source>Curr. Protoc. Mol. Biol.</source>
<volume>Chapter 1</volume>:<fpage>1.17.1-1.17.8</fpage>. doi: <pub-id pub-id-type="doi">10.1002/0471142727.mb0117s79</pub-id>, PMID: <pub-id pub-id-type="pmid">18265391</pub-id>
</mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname><given-names>Y.</given-names></name><name><surname>Yumoto</surname><given-names>N.</given-names></name><name><surname>Tokushige</surname><given-names>M.</given-names></name><name><surname>Fukui</surname><given-names>K.</given-names></name><name><surname>Ohya-Nishiguchi</surname><given-names>H.</given-names></name></person-group> (<year>1991</year>). <article-title>Purification and characterization of two types of fumarase from <italic>Escherichia coli</italic>1</article-title>. <source>J. Biochem.</source>
<volume>109</volume>, <fpage>728</fpage>&#x02013;<lpage>733</lpage>. doi: <pub-id pub-id-type="doi">10.1093/oxfordjournals.jbchem.a123448</pub-id>, PMID: <pub-id pub-id-type="pmid">1917897</pub-id>
</mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uphoff</surname><given-names>S.</given-names></name></person-group> (<year>2018</year>). <article-title>Real-time dynamics of mutagenesis reveal the chronology of DNA repair and damage tolerance responses in single cells</article-title>. <source>Proc. Natl. Acad. Sci.</source>
<volume>115</volume>, <fpage>E6516</fpage>&#x02013;<lpage>E6525</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1801101115</pub-id>, PMID: <pub-id pub-id-type="pmid">29941584</pub-id>
</mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>H.</given-names></name><name><surname>Polen</surname><given-names>T.</given-names></name><name><surname>Heuveling</surname><given-names>J.</given-names></name><name><surname>Wendisch</surname><given-names>V. F.</given-names></name><name><surname>Hengge</surname><given-names>R.</given-names></name></person-group> (<year>2005</year>). <article-title>Genome-wide analysis of the general stress response network in <italic>Escherichia coli</italic>: &#x003c3;S-dependent genes, promoters, and sigma factor selectivity</article-title>. <source>J. Bacteriol.</source>
<volume>187</volume>, <fpage>1591</fpage>&#x02013;<lpage>1603</lpage>. doi: <pub-id pub-id-type="doi">10.1128/jb.187.5.1591-1603.2005</pub-id>, PMID: <pub-id pub-id-type="pmid">15716429</pub-id>
</mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitehouse</surname><given-names>A. J.</given-names></name><name><surname>Libardo</surname><given-names>M. D. J.</given-names></name><name><surname>Kasbekar</surname><given-names>M.</given-names></name><name><surname>Brear</surname><given-names>P. D.</given-names></name><name><surname>Fischer</surname><given-names>G.</given-names></name><name><surname>Thomas</surname><given-names>C. J.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Targeting of fumarate hydratase from <italic>Mycobacterium tuberculosis</italic> using allosteric inhibitors with a dimeric-binding mode</article-title>. <source>J. Med. Chem.</source>
<volume>62</volume>, <fpage>10586</fpage>&#x02013;<lpage>10604</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b01203</pub-id>, PMID: <pub-id pub-id-type="pmid">31517489</pub-id>
</mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>S. A.</given-names></name><name><surname>Schwartzbach</surname><given-names>S. D.</given-names></name><name><surname>Guest</surname><given-names>J. R.</given-names></name></person-group> (<year>1988</year>). <article-title>Two biochemically distinct classes of fumarase in <italic>Escherichia coli</italic></article-title>. <source>Biochim. Biophys. Acta Protein Struct. Mol. Enzymol.</source>
<volume>954</volume>, <fpage>14</fpage>&#x02013;<lpage>26</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0167-4838(88)90050-7</pub-id>, PMID: <pub-id pub-id-type="pmid">3282546</pub-id>
</mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J. H.</given-names></name><name><surname>Bening</surname><given-names>S. C.</given-names></name><name><surname>Collins</surname><given-names>J. J.</given-names></name></person-group> (<year>2017</year>). <article-title>Antibiotic efficacy &#x02014; context matters</article-title>. <source>Curr. Opin. Microbiol.</source>
<volume>39</volume>, <fpage>73</fpage>&#x02013;<lpage>80</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mib.2017.09.002</pub-id>, PMID: <pub-id pub-id-type="pmid">29049930</pub-id>
</mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zalis</surname><given-names>E. A.</given-names></name><name><surname>Nuxoll</surname><given-names>A. S.</given-names></name><name><surname>Manuse</surname><given-names>S.</given-names></name><name><surname>Clair</surname><given-names>G.</given-names></name><name><surname>Radlinski</surname><given-names>L. C.</given-names></name><name><surname>Conlon</surname><given-names>B. P.</given-names></name><etal/></person-group>. (<year>2019</year>). <article-title>Stochastic variation in expression of the tricarboxylic acid cycle produces persister cells</article-title>. <source>MBio</source>
<volume>10</volume>:<fpage>e01930-19</fpage>. doi: <pub-id pub-id-type="doi">10.1128/mbio.01930-19</pub-id>, PMID: <pub-id pub-id-type="pmid">31530676</pub-id>
</mixed-citation></ref></ref-list></back></article>